Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGAV | P06756 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | LTK | P29376 | 1/20 | 0.30 |
| ▸ | GRK5 | P34947 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799324 | 1.00 | NNMT (0.50) | NNMTSIGMAR1GRM5CHRNB2CHRNA4 | |
| SCHEMBL8702527 | 0.94 | NNMT (0.45) | NNMTSIGMAR1GRM5CHRNB2CHRNA4 | |
| SCHEMBL18465420 | 0.92 | NNMT (0.44) | NNMTSIGMAR1GRM5CHRNB2CHRNA4 | |
| SCHEMBL30672241 | 0.88 | — | — | |
| SCHEMBL2449272 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL25313529 | 0.86 | NNMT (0.46) | NNMTSIGMAR1GRM5CHRNB2CHRNA4 | |
| SCHEMBL30172972 | 0.74 | ASIC3 (0.40) | NNMTGRM5CHRNB2CHRNA4ASIC3 | |
| SCHEMBL17546648 | 0.73 | NNMT (0.33) | NNMT | |
| SCHEMBL17546637 | 0.72 | MERTK (0.32) | NNMT | |
| SCHEMBL30100337 | 0.70 | CHEK1 (0.37) | NNMTCHEK1DAPK3PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| EP-1551341-A2 | USE OF Y-27632 AS AN AGENT TO PREVENT RESTENOSIS AFTER CORONARY ARTERY ANGIOPLASTY/STENT IMPLANTATION | The Trustees of Columbia University in the City of New York (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040028716-A1 | Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2004-02-12 | — | — | US | claimed |
| WO-2003105923-A2 | USE OF Y-27632 AS AN AGENT TO PREVENT RESTENOSIS AFTER CORONARY ARTERY ANGIOPLASTY/STENT IMPLANTATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 2003-12-24 | — | — | WO | claimed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | claimed |
| EP-0904271-A4 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | UNIV PRINCETON (US) | 2002-01-23 | — | — | EP | claimed |
| EP-0904271-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1999-03-31 | — | — | EP | claimed |
| WO-1997049705-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-12-31 | — | — | WO | claimed |
| WO-1997041115-A1 | 5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0215063-B1 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES | UNIV PRINCETON (US) | 1993-11-03 | — | — | EP | claimed |
| US-5223620-A | For antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-29 | — | — | US | claimed |
| EP-0215063-A4 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES. | UNIV PRINCETON (US) | 1987-11-23 | — | — | EP | claimed |
| US-4684653-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1987-08-04 | — | — | US | claimed |
| EP-0215063-A1 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES. | UNIV PRINCETON (US) | 1987-03-25 | — | — | EP | claimed |
| WO-1986005181-A1 | PYRIDO AD2,3-d BDPYRIMIDIN DERIVATIVES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1986-09-12 | — | — | WO | claimed |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-4684653-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0215063-A1 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES. | UNIV PRINCETON (US) | 1987-03-25 | — | — | EP | disclosed |
| WO-1986005181-A1 | PYRIDO AD2,3-d BDPYRIMIDIN DERIVATIVES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1986-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040028716-A1 | Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation | ROCK1, ROCK2, YES1 | NNMT 2705/4885SIGMAR1 3940/4885GRM5 3540/4885 |
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | NNMT 532/4885SIGMAR1 4403/4885GRM5 2071/4885 |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | TRPV1, SCN7A, TRPA1 | NNMT 1561/4885SIGMAR1 1030/4885GRM5 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.